Plasminogen activator inhibitor-1 is the main physiological regulator of tissue-type plasminogen activator in normal plasma. In addition to its critical function in fibrinolysis, plasminogen activator inhibitor-1 has been implicated in roles in other physiological and pathophysiological processes. To investigate structure-function aspects of mouse plasminogen activator inhibitor-1, the recombinant protein was expressed in Escherichia coli and purified. Five variant recombinant murine proteins (R76E, Q123K, R346A, R101A, and Q123K/R101A) were also generated using site-directed mutagenesis. The variant (R346A) was found to be defective in its inhibitory activity against tissue plasminogen activator relative to its wild-type counterpart. Enzyme-linked immunosorbent assay and surface plasmon resonance experiments demonstrated reduced vitronectin-binding affinity of the (Q123K) 
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). The Q123K/R101A variant demonstrated an even lower vitronectin-binding ability. Low density lipoprotein receptor-related protein binding was decreased for the (R76E) variant. It was also demonstrated that the plasminogen activator inhibitor-1/ vitronectin complex decreased the interaction of plasminogen activator inhibitor-1 with low density lipoprotein receptor-related protein. These results indicate that the complex interactions traditionally associated with different plasminogen activator inhibitor-1 functions apply to the murine system, thus showing a commonality of subtle functions among different species and evolutionary conservation of this protein. Further, this study provides additional evidence that the human hemostasis system can be studied effectively in the mouse, which is a great asset for investigations with gene-altered mice.
Plasminogen activator inhibitor-1 (PAI-1)
1 is a member of the serine protease inhibitor (SERPIN) superfamily and is the primary physiological regulator of urokinase (uPA) and tissue plasminogen activator (tPA) activity (1) . The inactivation of these latter proteases with PAI-1 is mediated through high affinity interactions, resulting in the formation of stable serpin-protease complexes (2) . PAI-1 has two major conformations, an active and a latent form. PAI-1 is a labile protein unless complexed with the plasma protein, vitronectin (VN), which stabilizes PAI-1 in an active form (3) . Otherwise, PAI-1 would be converted to a latent conformation and become inactivated. VN is also present in the extracellular matrix of many tissues and may serve to selectively localize PAI-1 function (3). The urokinase receptor (uPAR) also binds to VN, and the Nterminal region of this matrix protein contains the binding domain for both of these proteins (4) . Occupancy of the receptor by uPA results in an increased affinity for VN (5) , as well as activation of intracellular signaling reactions that regulate focal adhesion turnover (6) . Colocalization of this complex with integrins is the result of RGD-containing binding sites for ␣ v integrins in VN, which are located adjacent to the N-terminal domain of VN (7) . This complex can lead to local dissolution of extracellular matrix protein through activation of a proteolytic cascade. Regulation of this process occurs as a result of active PAI-1 sterically interfering with binding of either uPAR or integrin to VN (4, 8, 9) . Additionally, the interaction of PAI-1 with the surface-associated uPA-uPAR complex induces internalization of the complex via interaction with low density lipoprotein receptor-related protein (LRP) (10) . This process alters cytoplasmic signaling via uPA-uPAR. Because cell proliferation relies on a cycle of cell attachment, spreading, flattening (to initiate DNA synthesis), and then rounding up (the latter property resulting from disengagement of cell contacts through dissolution of the matrix), it would seem that alterations in PAI-1 expression could have a profound effect upon these cellular events.
Previous in vitro studies have elaborated structure/function relationships of human PAI-1, resulting in the delineation of functional domains that play a significant role in regulating its pathophysiology. Identification of critical sequences within specific domains has been achieved through structural and site-directed mutagenesis studies. For example, it is now known that human PAI-1 can inhibit VN-mediated cell adhesion and migration through interaction with VN. Sequences within human PAI-1, specifically encompassing the region 110 -147, primarily localized in the ␣ helix E, have been iden-tified that mediate this interaction (11, 12) . Further, a mutation at amino acid 123 (Q 3 K) has been shown to maintain PAI-1 serpin activity, but to significantly reduce affinity for VN (11) . In contrast, an R 3 A mutation at position 346, a critical residue in the reactive center loop, leads to a variant that interacts with the active site of target proteases, binds VN normally, but does not inhibit plasminogen activation (8) . In terms of LRP interactions, a cryptic site within the heparinbinding domain was identified (13) . An R 3 E mutation at amino acid position 76 of PAI-1 within this domain results in a protein with preserved inhibitor activity but diminished affinity for LRP. These targeted mutations of human PAI-1 indicate that functional changes at sites other than those specifically targeted are minor and, therefore, are ideal for delineating specific functional domains in select biological processes involving PAI-1. This study was aimed at an exploration of these functional domains in the murine PAI-1 through the expression and characterization of site-specific mutations in recombinant murine PAI-1. One practical value of this work is to evaluate the commonality of these subtle functions of PAI-1 across species, with special emphasis on the murine system, which is so widely employed for in vivo studies of PAI-1. The results of this investigation are described herein.
EXPERIMENTAL PROCEDURES
Materials-Restriction enzymes, T4 DNA ligase, reverse transcriptase, and TaqDNA polymerase were purchased from Promega (Madison, WI), unless otherwise specified. Oligonucleotides were synthesized by MWG Biotech (High Point, NC). The gel purification, PCR product purification, and plasmid mini/midi preparation kits were purchased from Qiagen (Valencia, CA). The chromogenic substrates H-DIle-Pro-Arg-pNA (S-2288) and pyro Glu-Phe-Lys-pNA (S-2403) were purchased from Chromogenix AB (West Chester, OH). Human VN, purified under non-denaturing conditions, was obtained from Promega. Human recombinant single-chain tPA (sctPA) was obtained from Genentech (San Francisco, CA). Human LRP was a gift from Dr. Dudley Strickland of the American Red Cross, and human PAI-1 and PAI-1 mutants were generated as described earlier (8, 11, 13) . All additional reagents were purchased from Fisher Scientific (Pittsburgh, PA). The data were analyzed by either Origin version 7.0 (Origin Lab, Northampton, MA) or GraphPad Prism version 3.0 (GraphPad Software Inc., San Diego, CA) software.
Construction of Mouse PAI-1 Variant Expression Vectors-The coding region of WT mouse PAI-1 (amino acid region 24 -402, Swiss-Prot primary accession no. P22777) was cloned in-frame with an N-terminal His 6 tag into the Escherichia coli expression vector pET15-b (Novagen, Madison, WI) using Nde-I/BamH-I sites. This construct lacks nucleotides encoding the first 23 amino acids that are thought to be the secretory signal region. The forward primer was 5Ј-GGAATTCCAT-CATATGTTTACCCCTCCGAGAA-3Ј. The reverse primer was 5Ј-CGCGGATCCTCAAGGCTCCATCAC-3Ј. The plasmids were transformed into DH5␣ competent E. coli cells (Invitrogen, Carlsbad, CA). The sequences were verified by DNA sequencing performed by the W. M. Keck Biotechnology Center (University of Illinois, UrbanaChampaign, IL). Mouse PAI-1 variants were generated with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as described in the manual, using the following oligonucleotides: R76E mutation forward primer, 5Ј-GGCACAGCTCATGCCCTCGAGCAGCT-CTCCAAGGAG-3Ј, and reverse primer, 5Ј-GCTCCTTGGAGAGCTGC-TCGAGGGCATGAGCTGTGC-3Ј; Q123K mutation forward primer, 5Ј-TTCCAGACTATGGTGAAAAAGGTGGACTTCTCAGAG-3Ј, and reverse primer, 5Ј-CCTCTGAGAAGTCCACCTTTTTCACCATAGTCTG-GA-3; R346A mutation forward primer, 5Ј-GCCTTTGTCATCTCAGC-CGCCATGGCCCCCACGGAG-3Ј, and reverse primer, 5Ј-CTCCGTGG-GGGCCATGGCTGAGATGACAAAGG-3Ј; R101A mutation forward primer, 5Ј-CTTTGTCCAGGCCGATCTAGAGCTGGTCCAGGGCTT-3Ј, and reverse primer, 5Ј-GAAGCCCTGGACCAGCTCTAGATCGGCCTG-GACAAA-3Ј. The Q123K/R101A double mutation was generated by using Q123K as a template. A new restriction site was incorporated into the primers to facilitate screening. The integrity of all mutant clones selected for protein expression was confirmed by DNA sequencing.
Expression and Purification of Recombinant Murine PAI-1 Proteins-Vectors containing mouse WT or variant murine PAI-1 were transformed into the E. coli expression strain BL21/DE3 (Novagen, Madison, WI). Expression of recombinant proteins was induced by adding isopropyl thio-b-D-galactoside (final concentration, 1 mM), into the cell suspension pregrown in Luria-Bertani medium supplemented with 100 g/ml ampicillin to A 600 ϭ 0.4 -0.5. The induced cells were grown at 37°C for another 3 h and then harvested by centrifugation at 10,000 ϫ g for 10 min. The pellets were stored at Ϫ70°C. For purification of the recombinant proteins, the cell pellets were re-suspended in BugBuster™ reagent (5 ml/gram pellet weight) (Novagen). Benzonase (1 l/ml) was added to reduce viscosity and to remove nucleic acids. The insoluble cell debris was removed by centrifugation at 16,000 ϫ g for 20 min at 4°C. The soluble PAI-1-containing supernatants were applied to an affinity chromatography column using nickel-nitrilotriacetic acid (NTA) agarose (Qiagen) resin. The column was then extensively washed with 0.5 M NaCl, 50 mM sodium phosphate, 0.1% Tween 80 (v/v), 10 mM imidazole, pH 7.0. The adsorbed proteins were eluted with 0.5 M NaCl, 50 mM sodium phosphate, 0.1% Tween 80 (v/v), 10 -150 mM imidazole gradient, pH 7.0. Fractions containing PAI-1 were pooled and subjected to gel-filtration chromatography using Sephadex G-25 (Sigma) to desalt proteins and to change the buffer to 10 mM phosphate buffer, pH 7.0. Pooled mouse PAI-1 preparations (except for the R76E variant) were further purified by heparin-agarose (Sigma) chromatography. Proteins were eluted with 10 mM sodium phosphate, pH 7.0, with a 0 -1 M NaCl gradient. (R76E)-PAI-1 was purified by a second NTA chromatography. Micro BCA™ protein assay kit (Pierce, Rockford, IL). Proteins were assessed for purity and size by SDS-10% PAGE under non-reducing conditions and stained with Coomassie Brilliant Blue.
Expression and purification of mouse PAI-1 variants were confirmed by Western blotting employing a polyclonal rabbit-anti-rat-PAI-1-IgG (American Diagnostica, Greenwich, CT) as the primary antibody and an alkaline phosphatase-conjugated goat-anti-rabbit-IgG (HϩL) (Bio-Rad, Hercules, CA) as the secondary antibody. The chromogen, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium was used for detection. The molecular weights of purified proteins were determined by ProteinChip (Ciphergen, Fremont, CA) using the Au chip.
Inhibitory Activity Assay-The inhibitory activity of PAI-1 toward tPA was determined by the Coatest™ PAI-1 assay (Chromogenix, West Chester, OH). Briefly, a fixed amount of tPA was added in excess to undiluted plasma, in which a portion rapidly forms an inactive complex with PAI-1. Plasminogen was then activated to plasmin by the residual tPA in the presence of a stimulator (fibrinogen degradation products).
The amount of plasmin formed was directly proportional to the residual tPA activity and, hence, inversely proportional to the PAI-1 activity in the sample. The amount of plasmin was determined by measuring the amidolytic activity with the chromogenic substrate, S-2403. The release of p-nitroaniline (pNA) was then determined by the absorbancy at 405 nm.
ELISA Assays-The capturing ligand, VN or LRP, was diluted to a concentration of 1 g/ml in phosphate-buffered saline buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4, pH 7.4). To coat the plates, 100 l/well of ligand was added to a NuncMaxiSorp 96-well microtiter plate (Fisher) and incubated overnight at 4°C. After three washes with phosphate-buffered saline buffer, the plate was blocked with 5% dried milk dissolved in washing buffer (phosphate-buffered saline, 0.1% Tween 80 (v/v)) and incubated for 2 h at room temperature. The plates were then washed 3ϫ with washing buffer, and PAI-1 variants were added and incubated at room temperature for 2 h. For studies involving analyses of PAI-1/tPA or PAI-1/VN complex interactions with LRP, 20 nM of each were incubated for 15 min at room temperature prior to addition to the LRP-coated plates. After three additional washings, the amount of PAI-1 captured by immobilized VN or LRP was visualized by addition of the primary antibody, polyclonal rabbit-anti-rat-PAI-1-IgG, followed by alkaline phosphatase-conjugated goat-anti-rabbit-IgG (HϩL) secondary antibody. The chromogen, p-nitrophenyl phosphate (Sigma), was used for detection. The absorbancy was measured at 405 nm and normalized against readings from noncoated wells.
Characterization of Mouse PAI-1 Variants by Surface Plasmon Resonance (SPR)-
The binding of label-free PAI-1 variants to VN was analyzed by SPR using a BIAcore™ 3000 (BIAcore AB, Uppsala, Sweden). All experiments were performed at 25°C employing HBS-EP (10 mM Hepes, 0.15 M NaCl, 3 mM EDTA, 0.005% polysorbate 20, pH 7.4) as running buffer at a flow rate of 20 l/min. VN (20 g/ml in 10 mM phosphate buffer, pH 4.0) was coupled to sensor chip CM-5 utilizing an amine-coupling kit (BIAcore AB) through the BIAcore flow cell at a rate of 5 ml/min for 6 min, resulting in ϳ3,000 response units (RUs) immobilized. The binding reactions were then carried out by injecting various concentrations of PAI-1 (diluted with running buffer) to the immobilized chip surface. Binding levels were determined by monitoring the resulting signal expressed as RUs. Between experiments, the chip surfaces were regenerated by washing with 30 l of 0.1 mM HCl, pH Ͻ 2.0, which did not alter the binding properties of the VN-immobilized chips. The data from sensorgrams were subtracted from those of a reference flow cell prepared by the same method, with the exception that VN was not immobilized on the chip. Kinetic constants were calculated from the association and dissociation rate curves generated by applying different concentrations of analytes onto ligand-immobilized surfaces, using a 1:1 binding model. All of the sensorgrams were analyzed utilizing the BioEvaluation software package version 3.0 (BIAcore AB).
FIG. 2.
Comparative analyses of plasminogen activator inhibitory activity of WT murine and human rPAI-1 and variants. Inhibitory activity was determined using single-chain tPA in a chromogenic assay. The relative levels of inhibitory activities of WT murine and human recombinant PAI-1 were considered to be 100%. The inhibitory activity of the variants was expressed as a percentage of WT PAI-1 activity. Assays were performed in four replicates, and values are expressed as the means Ϯ S.E. 
Measurement of the Functional
Half-life-PAI-1 was diluted to 20 g/ml in buffer containing 100 mM NaCl, 100 mM Hepes, 1 mM EDTA, 0.1% PEG-8000, 0.1 mg/ml bovine serum albumin, pH 7.4. The inhibitory activity against sctPA, at t ϭ 0, was designated as 100% activity. The proteins were then incubated at 37°C. Aliquots were removed at various times and the remaining sctPA inhibitory activity was determined and converted to percent relative to time zero.
RESULTS
Purification of PAI-1 Proteins-Typical final yields for recombinant WT PAI-1 were 3.8 mg/liter of culture. Yields for the variants were slightly better at 4.0 -4.8 mg/liter of culture. Fig.  1 represents SDS-PAGE and Western blotting analyses of the WT and the five variant (R76E, Q123K, R101A, Q123K/R101A, and R346A) proteins.
Plasminogen Activator Inhibitor Function-Analyses were performed on the purified rPAI-1 proteins with respect to their plasminogen activator inhibitory activity. The human and murine homologues of Q123K, R76E, and murine R101A and R101A/Q123K retain inhibitory activity, whereas murine and human (R346A)-PAI-1 demonstrated a significant reduction in activity (Fig. 2) , confirming a conserved functional domain between the human and murine molecules with respect to inhibitory activity.
VN Binding by ELISA-The VN-binding capacity of the Q123K, R101A, and Q123K/R101A variants of PAI-1 were compared with the WT protein and the other two PAI-1 variants (R76E and R346A) by ELISA. (Q123K)-PAI-1 demonstrated impaired binding capacity to VN relative to the WT protein and the other two variants (Fig. 3) , which is similar to the human protein studies. Additionally, (R101A)-PAI-1 and the double mutation (R101A/Q123K)-PAI-1 demonstrated even lower VNbinding abilities.
Kinetic Characterization of Murine rPAI-1 WT and Q123K Binding to VN by SPR-Approximately 3000
RUs of VN were immobilized onto a CM5 chip using an amine-coupling method. Various amounts of rPAI-1 were then injected onto the surface, and the binding levels were detected in real time (Fig. 4A) . A K D value for the interaction of murine WT PAI-1 with VN (K D ϭ 5.4 nM) was determined by nonlinear regression fitting of steady-state binding (Fig. 4B) . The association progress curves of WT PAI-1 binding were fit by a nonlinear single-exponential function to obtain the value of k obs . The k on was then determined by linear fitting of k obs as a function of PAI-1 concentrations (Fig. 4C) . Murine (Q123K)-PAI-1/VN binding at steady state was used to determine the K D value (K D ϭ 1800 nM) (Fig.  4D) . The k on was determined from the association phase of (Q123K)-PAI-1/VN binding curves and then used to calculate the k off value (Fig. 4E) (Fig. 4F) .
LRP-binding Abilities of Murine PAI-1 Variants-
The LRPbinding capacities of the altered PAI-1 forms were determined by ELISA experiments. (R76E)-PAI-1 demonstrated impaired LRP-binding ability, indicating that the LRP-binding domain was present in murine PAI-1 (Fig. 5A) . Also, the PAI-1 variants were denatured by dialysis against 4 M guanidinium-HCl and then refolded by removing denaturant. At least a fraction of the PAI-1-binding activity was enhanced by this unfolding/refolding process (Fig. 5A, gray columns) . Active PAI-1 demonstrated a higher LRP-binding ability than the latent form. PAI-1, in association with its protease substrate, tPA, also demonstrated enhanced association with LRP (Fig. 5B) . VN decreased the LRP-binding ability of murine PAI-1 (Fig. 5C ). This is most likely the result of steric hindrance due to the close proximity of the VN and LRP-binding sites.
Stability of Murine rPAI-1 Variants-The inhibitory activity against sctPA at t ϭ 0 was designated as 100%. The proteins were then incubated at 37°C. Aliquots were removed at the indicated times, and the remaining sctPA inhibitory activity was determined and converted to % relative to t ϭ 0. Each point represented the mean value of at least three replicates Ϯ S.E. These data were best fit by a singlephase exponential decay, consistent with a first-order reaction for conversion to latent from active PAI-1. The half-lives for murine WT PAI-1 and its variants calculated from these data were ϳ1.5 h (Fig. 6) . FIG. 5 . LRP-binding ability of WT murine PAI-1 and its variants. The LRP-binding capacity of WT PAI-1 and its variants was determined by ELISA experiments. A, (R76E)PAI-1 demonstrated impaired LRP-binding ability, indicating that LRP-binding domain was conserved in murine PAI-1. Also, PAI-1 variants were denatured by dialysis against 4 M guanidinium-HCl and then refolded by removing the denaturant. An increase in the PAI-1/LRP interaction was observed by this unfolding/refolding process (gray columns) relative to proteins that did not undergo the unfolding/refolding process (black columns). B, the LRP-binding ability of PAI-1 is increased if murine PAI-1 initially forms a complex with its protease substrates (gray columns) relative to PAI-1 alone (black columns). For the R346A mutant, the LRP-binding ability did not increase because its substrate-binding ability is impaired. C, VN decreases the LRP-binding ability of murine PAI-1 (gray columns) relative to PAI-1 alone (black columns). Because VN-and LRP-binding sites are in close proximity, this effect may be due to steric hindrance. DISCUSSION PAI-1 belongs to an expanding superfamily of SERPINs, folding into a conserved structure of three ␤-sheets and nine ␣-helices (14) . The anti-fibrinolytic activity toward its serine protease substrates, mainly uPA and tPA, under physiological conditions, has been mapped to the reactive center loop (RCL) designated from P15 to P4Ј (Gly 332 -Glu 350 ). Specifically, the P1 residue (Arg 346 ) determines the affinity and specificity toward the substrates, whereas the composition of other residues, especially the hinge region from P14 to P8, may affect loop insertion and consequently will affect the kinetics (15) . Unlike the common reversible "lock and key" model between inhibitors and serine proteases, the inhibition of PAI-1 toward its protease substrates has been described as a suicidal process following a branched pathway mechanism, with the majority of products being kinetically trapped as a covalently linked complex (16) . Theoretically, this provides extra regulatory opportunities during the different steps. In this study, we have demonstrated that the antifibrinolytic domain of human PAI-1 is conserved in its murine counterpart. The point mutation at the P1 site (R346A) effectively diminished its inhibitory activity, as shown for human PAI-1. In the presence of glycosaminoglycans such as heparin, PAI-1 becomes an effective inhibitor toward thrombin by a bridging mechanism (17) , with an even higher affinity than antithrombin, suggesting that PAI-1 not only regulates fibrinolysis through the plasminogen activation system, but also has potential to regulate the coagulation system. The heparin-binding site of PAI-1 has been identified and is located within several residues of helix D, including Arg 76 (18) . In this study, the murine R76E mutation, which completely changes the charge at this site, loses its binding ability toward a heparin-agarose resin during purification (data not shown), indicating that the heparin-binding domain is present in murine PAI-1.
VN is a 70-kDa glycoprotein that binds to PAI-1 and stabilizes its active conformation (3, 20 -22) . A number of studies have indicated that binding and stabilization of PAI-1 occurs through interactions with the somatomedin-B domain of VN, which consists of the N-terminal 40-amino acid residues of VN (21, 23) . Recently, results from crystallographic analyses of PAI-1 and the somatomedin-B domain of VN indicated that the binding interactions in this complex are primarily hydrophobic in nature, with the exception of a strong ionic interaction with Arg 101 located in the s2A-hE loop of PAI-1 (24) . A Q123K mutation in human PAI-1 resulted in significantly attenuated affinity for the matrix protein, VN, but retention of PAI-1 inhibitory activity (11) . We have generated the murine Q123K mutant and have observed effects upon VN binding similar to those described for human PAI-1 mutant. Kinetic studies using SPR revealed that the K D value of the Q123K-VN interaction was much lower than that of the WT protein, with a slower association and faster dissociation phase. Additionally, the Q123K/R101A double mutation further reduced VN-binding ability, indicating the electrostatic forces of Arg 101 is important for VN binding.
Several studies with human PAI-1 have shown that the uPA-uPAR complex on cell surfaces, in association with PAI-1, is endocytosed, and that this process is mediated by binding to LRP (25) (26) (27) (28) . The LRP-binding site in PAI-1 has been located to several residues that were also implicated in heparin binding (13) . This colocalization potentially indicates that PAI-1 may play opposite roles in regulating fibrinolysis that is dependent upon interaction with heparin or LRP, indicating a molecular switch capability. Similar to human studies, latent murine PAI-1 has a lower affinity for LRP than the active form (13) . It is believed that a high affinity site for LRP is generated on PAI-1 when in complex with a protease (13) . As evidenced from the present study, this cryptic LRP-binding site is also present in murine PAI-1, as indicated by the observation that the PAI-1-protease complex has a higher LRP-binding ability than PAI-1 alone. Our data also demonstrated that the murine PAI-1-VN complex had a lower affinity for LRP than active PAI-1 alone. This is significant, given the fact that active PAI-1 associates with VN in the extracellular matrix under normal physiological conditions, so active PAI-1 will not be degraded by endocytosis through LRP. This suggests that VN association will prevent active PAI-1 not only from latent conversion, but also from degradation, and therefore, sustain an active PAI-1 pool. However, when the local protease concentration increases, as would be expected during many physiological and pathological conditions, including cell migration, tumor growth, wound healing, and angiogenesis, active PAI-1 will complex with protease and concomitantly lose its affinity to VN. Therefore, PAI-1 will gain affinity for LRP and will be able to regulate its own function, as well as that of the protease, through LRP-mediated endocytosis. Taking the observation that the PAI-1-VN complex is able to inhibit cell migration by interfering with integrin and uPAR binding (8) , it is important to note that PAI-1 is probably pivotal in these events. The molecular mechanism by which PAI-1-VN complex blocks PAI-1-LRP binding is still unclear. However, this may be due to steric hindrance, considering the spatial proximity of the VN and LRP-binding site in PAI-1 (13, 24) .
Perhaps the most intriguing feature of PAI-1 is its structural metastability, making ligand interactions and in vivo functions even more perplexing. There are at least four conformational forms of PAI-1 that have so far been described (14) . The active form, with RCL protruding from other domains and being exposed to protease substrate binding, is the most unstable conformation. Active PAI-1 is automatically converted to another, much more stable conformation, the latent form, with a half-life of less than 2 h, indicating that this is a thermodynamically favorable event. Upon this unique conversion, RCL is inserted into the ␤-sheet A as the fourth strand, which generates a perfect anti-parallel ␤-sheet A (29) . This may explain why the latent form is thermodynamically more stable than the active form (14) . Meanwhile, the RCL is brought from a solvent-exposed position to a mostly buried one, thus providing a rationale for the low affinity of the latent form for its protease substrates. This latent conversion may also affect the ability of PAI-1 to bind VN and LRP (14) and, therefore, perhaps to exert a profound impact on its in vivo functions. The latent conversion provides a mechanism for regulating PAI-1 function, which may offer a novel strategy for drug targeting. FIG. 6 . Stability of murine WT and variant rPAI-1 inhibitory activity at 37°C. The stability of PAI-1 was determined by measuring residual activity as a function of time. The inhibitory activity against single-chain tPA at t ϭ 0 was designated as 100%. Aliquots were then removed from 37°C incubation at the indicated times, and tPA activity was determined. Each point represents the mean Ϯ S.E. of at least three replicates.
The other two possible conformations occur when PAI-1 forms covalent-linked complexes with its protease substrates, or when RCL is proteolytically cleaved, which is the substrate form.
Considering the multiple identified interactions of PAI-1, its unique structural features, along with mechanisms for regulating functional and nonfunctional conformations, PAI-1 would seemingly play a vital role in vivo. Surprisingly, PAI-1-deficient (PAI-1 Ϫ/Ϫ ) mice develop normally, are fertile, and remain relatively healthy in the absence of a specific challenge (30) . One possibility for this refractiveness in the absence of challenge is a possible redundancy of PAI-1 single functions with other proteins. On the other hand, a number of studies have indicated that a deficiency of PAI-1 in mice is manifested by altered responses to vascular and dermal injury (31) (32) (33) (34) , tumor growth and angiogenesis (19, (35) (36) (37) , and clot lysis (30) . As a result, under these challenge conditions, a functional redundancy may be overwhelmed, and the multiplicity of functions in a single protein may offer the most broad and economical response. In this way, a deficit of PAI-1 would be revealed.
Results from this study validate the PAI-1-deficient mouse as a unique resource for studying, in vivo, normal and pathological physiologies associated with PAI-1. Additional investigations utilizing mice with targeted mutations of PAI-1, within these domains, would serve to further elucidate mechanisms associated with the observed phenotypes in PAI-1-deficient mice in a number of challenge models.
